Protagonist Therapeutics, Inc.
Protagonist Therapeutics, Inc.（PTGX）股价预测与分析师目标价
华尔街共识、12 个月目标价、模型推演与 EPS/营收预期 — 来自分析师数据与历史行情。
ptgx · 股价预测 · 26 位分析师（近3月）· FMP · 更新于 2026年6月8日
分析师评级与共识
基于过去 3 个月内 26 位华尔街分析师
Buy
26 位分析师
共识
评级分布
12 个月目标价
High
$121
Consensus
$115
+17.7% upside
Low
$108
Median: $117 · Last Close: $98.03
12 个月目标价预测
历史收盘价 + 分析师 12 个月目标价预测区间
Consensus Target
$115.40
17.7% upside
High Target
$121
23.4%
Low Target
$108
10.2%
Current Price
$98.03
as of today
Based on analyst price targets, the PTGX stock price prediction for the next 12 months ranges from $108 to $121. The consensus PTGX price forecast of $115.40 implies 17.7% upside from the current price of $98.03.
短期股价预测
算法生成 · 每日更新
| Date | Predicted Price | Change |
|---|---|---|
| 2026-06-09 | $96.26 | ↓ 1.80% |
1-day model range: $95.72–$96.8. Peak: $96.8 (-1.80%).
长期股价预测
年度股价预测 · 2027 / 2028 / 2029 / 2030 / 2031
| Year | Avg Price | Change |
|---|---|---|
| 2027 | $157 | +59.7% |
| 2028 | $213 | +117.0% |
| 2029 | $258 | +163.6% |
| 2030 | $292 | +197.6% |
| 2031 | — | +220.7% |
基于技术分析的股价预测
14 项技术面信号（SMA×6 + EMA×6 + RSI + MACD）· EEAT 方法论透明
Market Sentiment
BEARISH
Based on 14 technical indicators
Refreshes daily from EOD close
Moving Averages · PTGX · Jun 9, 2026
最新分析师评级与调整
| Date | Brokerage | Action | Rating |
|---|---|---|---|
| 2026-05-06 | Citizens | Maintains | Market Outperform→Market Outperform |
| 2026-05-06 | Wedbush | Maintains | Outperform→Outperform |
| 2026-04-15 | Truist Securities | Maintains | Buy→Buy |
| 2026-04-07 | Clear Street | Maintains | Buy→Buy |
| 2026-03-19 | JP Morgan | Maintains | Overweight→Overweight |
| 2026-03-19 | Citigroup | Maintains | Buy→Buy |
| 2026-03-19 | Barclays | Maintains | Overweight→Overweight |
| 2026-03-19 | Leerink Partners | Maintains | Outperform→Outperform |
| 2026-03-03 | Goldman Sachs | Maintains | Neutral→Neutral |
| 2026-02-26 | Citizens | Maintains | Market Outperform→Market Outperform |
Wall Street analysts have recently issued updated ratings on Protagonist Therapeutics, Inc. (PTGX) stock. Of the recent 115 rating actions, 4 were upgrades and 2 were downgrades. 26 analysts currently cover PTGX.
分析师推荐趋势
PTGX analyst recommendation trends show stable buy-side sentiment over the past 6 months. Buy rating actions changed from 2 to 2 per month.
财务预测：EPS 与营收一致预期
Revenue This Year
$504M
↑ 78.2% YoY
Revenue Next Year
$144M
↓ 71.4% YoY
EPS This Year
$4.03
EPS Next Year
$-0.97
↓ 124.2% YoY
EPS ForecastReported vs Estimated
Analysts forecast PTGX EPS of $4.03 for the current fiscal year, based on estimates from 8 analysts. The PTGX revenue forecast is $504M for the current year. These are analyst consensus estimates via FMP / S&P Global.
关于预测与目标价
PTGX 股价预测由两类独立数据源支撑：来自 26 位华尔街分析师（S&P Global / FMP）的共识评级，以及基于历史日终价计算的技术分析。PTGX 的共识目标价为 $115.40（+17.7% 上行空间），分析师共识为 Buy。
PTGX 的短期预测（明日）为 $96.26（-1.80%）。 PTGX 对 2027 年的股价预测均值为 $157。 PTGX 对 2030 年的预测区间为 $274–$310。
Protagonist Therapeutics, Inc. 在 NASDAQ 上市，代码 PTGX。PTGX 在 2027 年的整体展望偏积极，在覆盖分析师中约 96% 对应 Buy 共识。
常见问题
PTGX 预测 · 8 个问题根据 26 位华尔街分析师，PTGX 的 12 个月平均目标价为 $115.40，最高 $121.00、最低 $108.00。若有图表，中位目标价可在上方查看。相对当前价 $98.03，隐含约 +17.7% 的上行空间。
· Analyst data: Financial Modeling Prep (FMP) · S&P Global Market Intelligence · Technical analysis: FMP /historical-price-eod/light · Updated: Hourly (analyst) · Daily (technical)
⚠ This information is provided for informational purposes only and does not constitute investment advice. Short-term and long-term price predictions are algorithmically generated and carry significant uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before making investment decisions.